SCHEMBL4428281

SCHEMBL4428281

CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)OC(C)(C)C

nearest known ligand 0.53

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 7/20 0.49
CTSB P07858 1/20 0.46
CTSS P25774 1/20 0.46
CTSK P43235 1/20 0.46
FCER2 P06734 2/20 0.44
REN P00797 1/20 0.42
MMP13 P45452 1/20 0.41
MMP9 P14780 1/20 0.40
MMP8 P22894 1/20 0.40
PTPN1 P18031 1/20 0.39
MAOB P27338 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7368069 1.00 GHSR (0.49) GHSRCTSBCTSSCTSKFCER2
SCHEMBL8717973 0.93 GHSR (0.43) GHSRCTSBCTSSCTSKFCER2
SCHEMBL6317980 0.93 GHSR (0.43) GHSRCTSBCTSSCTSKFCER2
SCHEMBL3273825 0.91 GHSR (0.47) GHSRCTSBCTSSCTSKREN
SCHEMBL6317705 0.90 GHSR (0.48) GHSRCTSBCTSSCTSKREN
SCHEMBL6317662 0.90 PTPN1 (0.45) GHSRCTSBCTSSCTSKFCER2
SCHEMBL3273983 0.90 GHSR (0.45) GHSRCTSBCTSSCTSKREN
SCHEMBL3268342 0.90 GHSR (0.45) GHSRCTSBCTSSCTSKREN
SCHEMBL3266843 0.88 GHSR (0.47) GHSRCTSBCTSSCTSKMMP13
SCHEMBL6318464 0.88 CTSB (0.45) GHSRCTSBCTSSCTSKREN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0869974-B1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK AS (DK) 2009-03-04 EP disclosed
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
US-6784158-B1 SECRETAGOGUE WHICH CAN BE USED IN TREATING MEDICAL DISORDERS RESULTING FROM A DEFICIENCY IN GROWTH HORMONE NOVO NORDISK A/S (DK) 2004-08-31 US disclosed
US-20040063641-A1 Use of growth hormone or a growth hormone secretagogue for promoting bone formation RASCHKE MICHAEL (DE) 2004-04-01 US disclosed
EP-1060190-B1 NEW SALT FORMS OF (2E)- 5-AMINO-5- METHYLHEX-2- ENOIC ACID N-METHYL-N-((1R)-1-(N- METHYL-N-((1R)-1-(METHYLCARBAMOYL)-2- PHENYLETHYL)CARBAMOYL)-2- (2-NAPHTYL)ETHYL)AMIDE NOVO NORDISK AS (DK) 2003-11-19 EP disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US disclosed
US-20020128178-A1 Use of growth hormone or a growth hormone secretagogue for promoting bone formation RASCHKE MICHAEL (DE) 2002-09-12 US disclosed
US-6281247-B1 GLANDULAR DISORDERS; ANIMAL GROWTH REGULATORS NOVO NORDISK A/S (DK) 2001-08-28 US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
WO-1999064456-A1 A METHOD FOR PREPARING A COMPOUND WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1999-12-16 WO disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US disclosed
EP-0941115-A1 USE OF GROWTH HORMONE OR A GROWTH HORMONE SECRETAGOGUE FOR PROMOTING BONE FORMATION NOVO NORDISK A/S (DK) 1999-09-15 EP disclosed
WO-1999045029-A1 NEW SALT FORMS OF (2E)- 5-AMINO-5- METHYLHEX-2- ENOIC ACID N-METHYL-N-((1R)-1-(N- METHYL-N-((1R)-1-(METHYLCARBAMOYL)-2- PHENYLETHYL)CARBAMOYL)-2- (2-NAPHTYL)ETHYL)AMIDE NOVO NORDISK A/S (DK) 1999-09-10 WO disclosed
EP-0907374-A1 GROWTH HORMONE COMPONENT AND BONE ANTI-RESORPTIVE AGENT IN CYCLIC (COHERENCE) TREATMENT OF OSTEOPOROSIS NOVO NORDISK A/S (DK) 1999-04-14 EP disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
WO-1998019699-A1 USE OF GROWTH HORMONE OR A GROWTH HORMONE SECRETAGOGUE FOR PROMOTING BONE FORMATION NOVO NORDISK A/S (DK) 1998-05-14 WO disclosed
WO-1997046252-A1 GROWTH HORMONE COMPONENT AND BONE ANTI-RESORPTIVE AGENT IN CYCLIC (COHERENCE) TREATMENT OF OSTEOPOROSIS NOVO NORDISK A/S (DK) 1997-12-11 WO disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 GHSR 2/4885CTSB 967/4885CTSS 2319/4885
US-20040063641-A1 Use of growth hormone or a growth hormone secretagogue for promoting bone formation GHSR, GHRHR, BMP2 GHSR 1/4885CTSB 142/4885CTSS 298/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR GHSR 2/4885CTSB 1232/4885CTSS 2636/4885
US-20020128178-A1 Use of growth hormone or a growth hormone secretagogue for promoting bone formation GHSR, GHRHR, BMP2 GHSR 1/4885CTSB 142/4885CTSS 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.